Bion Environmental corrects 10-K statement on RNG project engineering engagement
Bitget2026/10/06 12:52Bion Environmental Technologies issued a correction to its Form 10-K filed Sept. 29, 2026, citing an inaccurate statement. The filing said an engineering company had been engaged for pilot testing and a FEL-3 study for a large RNG project. Management said no agreements have been executed with engineering firms for pilot testing or FEL-2/3 engineering services. Talks continue with several engineering companies. No assurance any deal will be signed. Disclosures tied to engineering work for an August grant application remain unchanged. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bion Environmental Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001079973-26-001322), on October 06, 2026, and is solely responsible for the information contained therein.
- Bion Environmental Technologies issued a correction to its Form 10-K filed Sept. 29, 2026, citing an inaccurate statement.
- The filing said an engineering company had been engaged for pilot testing and a FEL-3 study for a large RNG project.
- Management said no agreements have been executed with engineering firms for pilot testing or FEL-2/3 engineering services.
- Talks continue with several engineering companies. No assurance any deal will be signed.
- Disclosures tied to engineering work for an August grant application remain unchanged.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
